Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PDM608 in Healthy Adults
NCT05950906Phase 1Completed
- Sponsor
- Calibr-Skaggs Institute for Innovative Medicines
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PDM608 in Parkinson's disease (PD) (4 arms), sponsored by Calibr-Skaggs Institute for Innovative Medicines. Primary endpoints: Number of Participants With Adverse Events, Number of Participants With Clinically Significant Abnormal Laboratory Test Results and 4 more. Started Jun 2023; status: completed.
02
Drugs
PDM608
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05950906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950906.